These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27920397)

  • 1. Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety.
    Lee DK; Chang VY; Kee T; Ho CM; Ho D
    SLAS Technol; 2017 Jun; 22(3):276-288. PubMed ID: 27920397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and biology of pediatric acute lymphoblastic leukemia.
    Kato M; Manabe A
    Pediatr Int; 2018 Jan; 60(1):4-12. PubMed ID: 29143423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia.
    Parentelli AS; Phulpin-Weibel A; Mansuy L; Contet A; Trechot P; Chastagner P
    Pediatr Blood Cancer; 2013 Feb; 60(2):340-1. PubMed ID: 23129570
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.
    Asselin B
    Future Oncol; 2016 Jul; 12(13):1609-21. PubMed ID: 27086555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
    Ramsey LB; Janke LJ; Payton MA; Cai X; Paugh SW; Karol SE; Kamdem Kamdem L; Cheng C; Williams RT; Jeha S; Pui CH; Evans WE; Relling MV
    PLoS One; 2015; 10(8):e0135134. PubMed ID: 26252865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
    J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
    Ariës IM; van den Dungen RE; Koudijs MJ; Cuppen E; Voest E; Molenaar JJ; Caron HN; Pieters R; den Boer ML
    Haematologica; 2015 Apr; 100(4):e132-6. PubMed ID: 25480501
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.
    Krishnan V; Rajasekaran AK
    Clin Pharmacol Ther; 2014 Feb; 95(2):168-78. PubMed ID: 24013811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leukemia and malnutrition. II. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ
    Rev Invest Clin; 1990; 42(2):81-7. PubMed ID: 2267453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.
    Al-Ghobashy MA; Hassan SA; Abdelaziz DH; Elhosseiny NM; Sabry NA; Attia AS; El-Sayed MH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():88-94. PubMed ID: 27802917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
    Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
    Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
    J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
    Rose-James A; Shiji R; Kusumakumary P; Nair M; George SK; Sreelekha TT
    Med Oncol; 2016 Sep; 33(9):98. PubMed ID: 27449773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.